GeoVax Labs Secures $4.5 Million in Registered Direct Offering to Advance Clinical Research

Biotechnology company GeoVax Labs has initiated a strategic financial move to bolster its research and development efforts, announcing a registered direct offering of securities valued at $4.5 million. The offering, structured as a purchase of common stock and accompanying warrants, represents a critical funding mechanism for the company's ongoing clinical programs.

Under the terms of the agreement with a healthcare-focused institutional investor, GeoVax will issue 3,435,115 shares of common stock and warrants at a combined purchase price of $1.31 per share. The warrants, exercisable upon shareholder approval, will have a five-year term and an exercise price matching the offering price.

The funding comes at a crucial time for GeoVax, which is currently conducting multiple clinical trials across two primary therapeutic areas. In the infectious disease space, the company is advancing a next-generation COVID-19 vaccine, GEO-CM04S1, with ongoing Phase 2 clinical trials targeting immunocompromised patients, chronic lymphocytic leukemia patients, and as a potential booster for individuals previously vaccinated with mRNA vaccines.

Simultaneously, the company is progressing its oncology program, which includes Gedeptin®, an innovative oncolytic solid tumor gene-directed therapy. Having completed a Phase 1/2 clinical trial for advanced head and neck cancers, GeoVax is preparing to launch a Phase 2 trial evaluating Gedeptin® in combination with an immune checkpoint inhibitor.

The newly secured funds will be allocated to working capital and general corporate purposes, providing GeoVax with additional financial flexibility to continue its research and development initiatives. The offering, priced at-the-market under Nasdaq rules, demonstrates the company's strategic approach to maintaining financial momentum while pursuing potentially groundbreaking medical innovations.

This capital raise underscores GeoVax's commitment to advancing therapeutic solutions in both infectious diseases and oncology, with potential implications for addressing critical medical challenges facing immunocompromised patients and cancer treatment.